Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 2.97B 3.42B 2.74B 2.56B 4.79B 328B 4.89B 32.65B 12.64B 158B 12.84B 12.57B 549B P/E Ratio 2026 *
22.2x
P/E Ratio 2027 * 16.3x
Enterprise Value 2.95B 3.4B 2.72B 2.55B 4.76B 325B 4.85B 32.4B 12.54B 157B 12.75B 12.47B 545B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 3.15x
Free-Float
31.63%
Yield 2026 *
1.68%
Yield 2027 * 2.02%
3 years 50.88
Extreme 50.88
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 26/07/2007
Director of Finance/CFO - 31/12/2000
Chief Tech/Sci/R&D Officer - 31/12/2013
Director TitleAgeSince
Chairman - 16/07/2021
Director/Board Member - 26/07/2007
Director/Board Member - 26/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
-27.31%-.--% - - 3.42B
+2.16%+3.17%+43.57%+160.28% 1,035B
-0.07%+4.45%+53.50%+48.95% 574B
-0.08%-0.08%+17.37%+62.66% 397B
+0.21%+0.77%+21.19%+15.95% 324B
+0.08%-1.63%+23.59%+15.23% 281B
+0.34%+3.48%+24.48%+34.39% 278B
-0.21%+3.77%-45.64%-48.40% 193B
+4.84%+2.45%+21.33%+61.85% 191B
+3.61%-2.56%+15.16%+61.12% 156B
Average -1.82%+1.68%+19.40%+45.78% 381.1B
Weighted average by Cap. +0.53%+2.39%+29.34%+72.87%

Financials

2026 *2027 *
Net sales 774M 892M 713M 669M 1.25B 85.4B 1.28B 8.51B 3.3B 41.17B 3.35B 3.28B 143B 913M 1.05B 842M 789M 1.47B 101B 1.5B 10.04B 3.89B 48.56B 3.95B 3.86B 169B
Net income 133M 153M 123M 115M 215M 14.67B 219M 1.46B 566M 7.07B 575M 563M 24.59B 183M 210M 168M 158M 295M 20.15B 301M 2.01B 777M 9.71B 790M 773M 33.76B
Net Debt -22.53M -25.97M -20.77M -19.46M -36.36M -2.49B -37.12M -248M -95.93M -1.2B -97.47M -95.37M -4.17B -90.52M -104M -83.44M -78.19M -146M -9.99B -149M -995M -385M -4.81B -392M -383M -16.74B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
58.05EUR
Average target price
75.38EUR
Spread / Average Target
+29.85%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!